Putting the award page together from the records…
Putting the award page together from the records…
Emergent Biosolutions Canada Inc received this contract from Aspr/Orm-Sns, Office of Assistant Secretary for Preparedness and Response: $228.93M obligated so far for drugs and biologicals. It runs to 2027-03-30, or to 2029-05-30 if every option is exercised.
Key facts · data as of Oct 21, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 21, 2026.
Cite this page: SpendQuery, Award 75A50119C00037, data as of Oct 21, 2026, https://spendquery.com/award?id=CONT_AWD_75A50119C00037_7505_-NONE-_-NONE-
Emergent Biosolutions Canada Inc: all federal awards · Department of Health and Human Services: spending · Aspr/Orm-Sns: what it buys · The follow-on: recompete brief
VIGIV BUY AND ASSOCIATED SERVICES
Up for re-bid: ends 2027-03-30. Recompete brief →
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
10 actions since 2023-03-20. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-03-23 | P00017 | Option exercised | $53.73M | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATES SERVICES FOR UP TO 10 YEARS. |
| 2025-07-02 | P00016 | Option exercised | $51.92M | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATES SERVICES FOR UP TO 10 YEARS. |
| 2025-06-30 | P00015 | Change order | $0 | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS. |
| 2025-06-13 | P00014 | Change order | $0 | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS. |
| 2025-06-02 | P00013 | Change order | $0 | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS. |
| 2025-03-04 | P00012 | Supplemental agreement (work within scope) | $0 | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS. |
| 2024-06-10 | P00011 | Option exercised | $62.70M | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS. |
| 2024-02-22 | P00010 | Supplemental agreement (work within scope) | $0 | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATED SERVICES FOR UP TO 10 YEARS. |
| 2023-05-19 | P00009 | Option exercised | $60.58M | EXTENSION OF ORDERING PERIOD FOR OPTION 5/YEAR 5 TO 5/30/2023. |
| 2023-03-20 | P00008 | Supplemental agreement (work within scope) | $0 | EXTENSION OF ORDERING PERIOD FOR OPTION 5/YEAR 5 TO 5/30/2023. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-21). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗